Therapeutics targeting B7-H4 could produce significant synergistic outcomes, eliminating cancer cells and favorably altering the tumor microenvironment, as B7-H4 was expressed on tumor cells and tumor-associated macrophages in various cancers. The gene discussed is VTCN1; the disease is neoplasm.